Gamida Cell Ltd
NASDAQ:GMDA
Intrinsic Value
Gamida Cell Ltd. operates as a clinical stage biopharmaceutical company. [ Read More ]
The intrinsic value of one
GMDA
stock under the Base Case scenario is
2.2636
USD.
Compared to the current market price of 0.0327 USD,
Gamida Cell Ltd
is
Undervalued by 99%.
Gamida Cell Ltd's market capitalization is 4.7m USD.
GMDA stock price is 0.0327 USD.
GMDA stock price (0.0327 USD) is 99% less than its Intrinsic Value (2.2636 USD).
GMDA stock price (0.0327 USD) is 59% less than its Relative Value (0.0806 USD). Open Relative Valuation
GMDA.
GMDA's long-term liabilties (105m USD) exceed its long-term assets (102m USD).
GMDA has positive Net Debt. This means that the company has more debt (73m USD) than cash and short-term investments (47m USD).
GMDA has positive Gross Profit for the last twelve months.
GMDA's ROE (Return on Equity) has significantly increased in the last 3 years from -129% to 1 151%.
GMDA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -475% to -161%, and is approaching profitability.
GMDA's short-term assets (55m USD) exceed its short-term liabilties (25m USD).
GMDA has negative Operating Income for the last twelve months.
GMDA has negative Net Income for the last twelve months.
GMDA's ROE (Return on Equity) for the past 12 months is very high and is equal to 1 151%.
GMDA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -161%.
GMDA has negative Free Cash Flow for the last twelve months.
GMDA has negative three-year average ROE (Return on Equity): -179%. The company is not efficient at transforming stockholders' equity into net income.
GMDA has negative three-year average ROIC (Return on Invested Capital): -287%. The company is not efficient at using invested capital to generate operating income.
GMDA's D/E (Debt to Equity) is very low and is equal to -24.77.
GMDA's Altman Z-Score is very low and is equal to -8.76.
GMDA doesn't generate enough operating income (-73m USD) to safely cover interest payments on its debt (6m USD).
Fundamental Analysis
Gamida Cell Ltd
Balance Sheet Decomposition
Gamida Cell Ltd
| Current Assets | 54.5m |
| Cash & Short-Term Investments | 46.6m |
| Receivables | 1.6m |
| Other Current Assets | 6.4m |
| Non-Current Assets | 47.6m |
| PP&E | 44.4m |
| Other Non-Current Assets | 3.2m |
| Current Liabilities | 25.2m |
| Accounts Payable | 10m |
| Accrued Liabilities | 8.7m |
| Other Current Liabilities | 6.5m |
| Non-Current Liabilities | 79.9m |
| Long-Term Debt | 73m |
| Other Non-Current Liabilities | 6.9m |
Earnings Waterfall
Gamida Cell Ltd
|
Revenue
|
1.8m
USD
|
|
Cost of Revenue
|
-1.5m
USD
|
|
Gross Profit
|
330k
USD
|
|
Operating Expenses
|
-73m
USD
|
|
Operating Income
|
-72.6m
USD
|
|
Other Expenses
|
9.6m
USD
|
|
Net Income
|
-63m
USD
|
Free Cash Flow Analysis
Gamida Cell Ltd
What is Free Cash Flow?
GMDA Profitability Score
Profitability Due Diligence
Gamida Cell Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Gamida Cell Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
GMDA Solvency Score
Solvency Due Diligence
Gamida Cell Ltd's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Gamida Cell Ltd's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GMDA Price Targets Summary
Gamida Cell Ltd
Ownership
GMDA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
GMDA Price
Gamida Cell Ltd
| Average Annual Return | -18.33% |
| Standard Deviation of Annual Returns | 73.82% |
| Max Drawdown | -100% |
| Market Capitalization | 4.7m USD |
| Shares Outstanding | 132 639 000 |
| Percentage of Shares Shorted | 7.9% |
Company Profile
Gamida Cell Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Gamida Cell Ltd. operates as a clinical stage biopharmaceutical company. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).
You don't have any saved screeners yet
